-
公开(公告)号:US08088941B2
公开(公告)日:2012-01-03
申请号:US12149336
申请日:2008-04-30
IPC分类号: C07F9/02 , A61K31/155
CPC分类号: C07F9/094 , A61K38/00 , C07F9/6518 , C07K7/06 , C07K14/4703 , C07K14/4705 , C07K2299/00 , C12N9/1205
摘要: Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.
摘要翻译: 公开了旨在允许与GSK-3的结合位点相互作用并因此通过抑制底物结合而抑制GSK-3活性的新型化合物。 进一步公开的是包含其的药物组合物和在治疗GSK-3介导的病症中使用它们的方法。
-
2.
公开(公告)号:US20100093704A1
公开(公告)日:2010-04-15
申请号:US12447381
申请日:2007-10-25
申请人: Moshe Portnoy , Irit Gil-Ad , Avraham Weizman
发明人: Moshe Portnoy , Irit Gil-Ad , Avraham Weizman
IPC分类号: A61K31/551 , C07D243/10 , A61P25/22 , A61P25/24 , A61P25/18 , A61P25/28
CPC分类号: C07D495/04 , A61K31/551 , A61K47/542 , A61K47/55 , C07D403/04
摘要: The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders.
摘要翻译: 本发明提供用于治疗心理和/或精神疾病或病症的新型化合物和药物组合物。
-
公开(公告)号:US07378432B2
公开(公告)日:2008-05-27
申请号:US11280209
申请日:2005-11-17
IPC分类号: A01N43/64 , C07D249/04
CPC分类号: C07F9/094 , A61K38/00 , C07F9/6518 , C07K7/06 , C07K14/4703 , C07K14/4705 , C07K2299/00 , C12N9/1205
摘要: Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.
-
公开(公告)号:US08394790B2
公开(公告)日:2013-03-12
申请号:US12447381
申请日:2007-10-25
申请人: Moshe Portnoy , Irit Gil-Ad , Avraham Weizman
发明人: Moshe Portnoy , Irit Gil-Ad , Avraham Weizman
IPC分类号: A61P25/18 , A61K31/554 , A61K31/55 , C07D495/00 , C07D281/02
CPC分类号: C07D495/04 , A61K31/551 , A61K47/542 , A61K47/55 , C07D403/04
摘要: The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders.
摘要翻译: 本发明提供用于治疗心理和/或精神疾病或病症的新型化合物和药物组合物。
-
公开(公告)号:US20100279990A1
公开(公告)日:2010-11-04
申请号:US12308299
申请日:2007-06-08
申请人: Irit Gil-Ad , Moshe Portnoy , Avraham Weizman , Liat Lomnitski
发明人: Irit Gil-Ad , Moshe Portnoy , Avraham Weizman , Liat Lomnitski
IPC分类号: A61K31/56 , C07C215/42 , A61K31/137 , A61P35/00 , A61P17/00 , A61P17/06 , A61P35/02 , A61P19/02 , A61P29/00 , C07D405/12 , A61K31/4525
CPC分类号: C07C211/42 , C07C2602/10 , C07D405/12
摘要: The present invention provides a compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR6, OC(O)R6, C(O)R6 C(S)R6, CO2R6, C(O)SR6, C(O)NR6R7, C(S)NR6R7, NR6R7, NR6C(O)R7, NR6C(S)R7, NR6C(O)NR7R8, NR6C(S)NR7R8, NR6SO2R7, NR6SO2NR7R8, SR6, SC(O)R6, SC(O)NR6R7, S(O)R6, SO2R6, SO2NR6R7, or NR6SO2R7R8. Also provided is a pharmaceutical composition that includes one or more compounds of the present invention, and methods of therapeutically using and processes for producing such compounds and compositions.
摘要翻译: 本发明提供式A-L-B(I)化合物或其药学上可接受的盐,酯或前药,其中A是精神药物衍生物; L是包含两个碳原子的连接基团; 并且B是包含至少一个式Q取代基的烷基,烯基,炔基或芳烷基,其中:烷基,烯基,炔基或芳烷基任选被一个或多个卤素,羟基,氰基,硝基,氨基或硫醇取代; 并且Q是OR 6,OC(O)R 6,C(O)R 6 C(S)R 6,CO 2 R 6,C(O)SR 6,C(O)NR 6 R 7,C(S)NR 6 R 7,NR 6 R 7,NR 6 C(O) NR 6 C(O)NR 6 R 7,NR 6 C(O)NR 7 R 8,NR 6 C(S)NR 7 R 8,NR 6 SO 2 R 7,NR 6 SO 2 NR 7 R 8,SR 6,SC(O)R 6,SC(O)NR 6 R 7,S(O)R 6,SO 2 R 6,SO 2 NR 6 R 7或NR 6 SO 2 R 7 R 8。 还提供了包含一种或多种本发明化合物的药物组合物,以及治疗用途的方法和制备这些化合物和组合物的方法。
-
公开(公告)号:US20100130549A1
公开(公告)日:2010-05-27
申请号:US12522637
申请日:2008-01-10
申请人: Irit Gil-Ad , Moshe Portnoy , Avraham Weizman , Liat Lomnitski
发明人: Irit Gil-Ad , Moshe Portnoy , Avraham Weizman , Liat Lomnitski
IPC分类号: A61K31/4525 , A61K31/135 , A61P25/00 , A61P35/00
CPC分类号: A61K31/135 , A61K31/14 , A61K31/4525
摘要: The present invention provides a method for treating or preventing a disease or disorder treatable by the inhibition of serotonin reuptake in a patient, and/or norepinephrine reuptake and/or dopamine reuptake in a patient, the method comprising administering to the patient a neurotransmitter reuptake inhibiting-effective amount of at least one compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogean halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR6, OC(O)R6, C(O)R6, C(S)R6, CO2R6, C(O)SR6, C(O)NR6R7, C(S)NR6R7, NR6R7, NR6C(O)R7, NR6C(S)R7, NR6C(O)NR7R8, NR6C(S)NR7R8, NR6SO2R7, NR6SO2NR7R8, SR6, SC(O)R6, SC(O)NR6R7, S(O)R6, SO2R6, SO2NR6R7, or NR6SO2NR7R8.
摘要翻译: 本发明提供了一种治疗或预防通过抑制患者血清素再摄取和/或去甲肾上腺素再摄取和/或患者多巴胺再摄取而可治疗的疾病或病症的方法,所述方法包括向患者施用神经递质再摄取抑制 - 有效量的至少一种式ALB(I)化合物或其药学上可接受的盐,酯或前药,其中A是精神药物衍生物; L是包含两个碳原子的连接基团; 并且B是包含至少一个式Q取代基的烷基,烯基,炔基或芳烷基,其中:烷基,链烯基,炔基或芳烷基任选被一个或多个卤代卤素,羟基,氰基,硝基,氨基或硫醇取代 ; (O)R 6,C(O)R 6,C(O)SR 6,C(O)NR 6 R 7,C(S)NR 6 R 7,NR 6 R 7,NR 6 C(O)R 7 ,NR6C(S)R7,NR6C(O)NR7R8,NR6C(S)NR7R8,NR6SO2R7,NR6SO2NR7R8,SR6,SC(O)R6,SC(O)NR6R7,S(O)R6,SO2R6,SO2NR6R7或NR6SO2NR7R8。
-
公开(公告)号:US20080312188A1
公开(公告)日:2008-12-18
申请号:US12149336
申请日:2008-04-30
IPC分类号: A61K31/675 , C07F9/6503 , A61P3/04 , A61P3/10 , C07F9/58
CPC分类号: C07F9/094 , A61K38/00 , C07F9/6518 , C07K7/06 , C07K14/4703 , C07K14/4705 , C07K2299/00 , C12N9/1205
摘要: Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.
摘要翻译: 公开了旨在允许与GSK-3的结合位点相互作用并因此通过抑制底物结合而抑制GSK-3活性的新型化合物。 进一步公开的是包含其的药物组合物和在治疗GSK-3介导的病症中使用它们的方法。
-
公开(公告)号:US20060069066A1
公开(公告)日:2006-03-30
申请号:US11280209
申请日:2005-11-17
IPC分类号: A61K31/675 , C07F9/6503 , C07F9/58
CPC分类号: C07F9/094 , A61K38/00 , C07F9/6518 , C07K7/06 , C07K14/4703 , C07K14/4705 , C07K2299/00 , C12N9/1205
摘要: Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.
摘要翻译: 公开了旨在允许与GSK-3的结合位点相互作用并因此通过抑制底物结合而抑制GSK-3活性的新型化合物。 进一步公开的是包含其的药物组合物和在治疗GSK-3介导的病症中使用它们的方法。
-
-
-
-
-
-
-